Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KA44
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
KA44 is a novel hybrid homo-aza (lactam) steroidal antimetabolite being investigated for the treatment of gastrointestinal malignancies, specifically pancreatic and colorectal cancers. It belongs to a class of steroidal conjugates designed to enhance selectivity and toxicokinetics compared to conventional antimetabolites like 5-fluorouracil and methotrexate. KA44 acts as a dual inhibitor of thymidylate synthase (TS) and dihydrofolate reductase (DHFR), leading to the inhibition of DNA synthesis, induction of apoptosis, and cell cycle arrest. Preclinical studies have demonstrated its cytostatic efficacy against various carcinoma cell lines, providing a rationale for its further evaluation as a next-generation therapeutic for resistant gastrointestinal cancers.
Beyond the preview
Go deeper on KA44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KA44.